MoonLake Immunotherapeutics (MLTX) Stock Statistics & Valuation Metrics

MoonLake Immunotherapeutics has a market cap or net worth of $983.83M. The enterprise value is $602.11M.

Market Cap

$983.83M

Enterprise Value

$602.11M

MoonLake Immunotherapeutics has 85,106,680 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

85,106,680

Owned by Insiders

26.65%

Owned by Institutions

7.46%

MoonLake Immunotherapeutics’s return on equity (ROE) is -0.75 and return on invested capital (ROIC) is -64.40%.

Return on Equity (ROE)

-0.75

Return on Assets (ROA)

-0.54

Return on Invested Capital (ROIC)

-64.40%

Return on Capital Employed (ROCE)

-0.65

Revenue Per Employee

0

Profits Per Employee

-1.75M

Employee Count

130

Asset Turnover

0.00

Inventory Turnover

0.00

The current PE Ratio of MoonLake Immunotherapeutics is -2.93. MoonLake Immunotherapeutics’s PEG ratio is 0.26.

PE Ratio

-2.93

PS Ratio

0.00

PB Ratio

2.42

Price to FCF

-3.77

Price to Operating Cash Flow

-3.78

PEG Ratio

0.26

In the last 12 months, MoonLake Immunotherapeutics had revenue of 0 and earned -227.32M in profits. Earnings per share was -3.53.

Revenue

0

Gross Profit

-2.62M

Operating Income

-244.83M

Pretax Income

-229.71M

Net Income

-227.32M

EBITDA

-219.85M

Earnings Per Share (EPS)

-3.53

In the last 12 months, operating cash flow was -244.04M and capital expenditures 0, giving a free cash flow of -244.04M billion.

Operating Cash Flow

-244.04M

Free Cash Flow

-244.04M

Free Cash Flow per Share

-2.86

MoonLake Immunotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-26.53%

Earnings Yield

-29.63%

Beta

0.67

52-Week Price Change

1.98%

50-Day Moving Average

12.35

200-Day Moving Average

16.43

Relative Strength Index (RSI)

41.80

Average Volume (3m)

1.71M

MoonLake Immunotherapeutics upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).

Last Earnings Date

Nov 04, 2026

Next Earnings Date

Mar 04, 2027

Ex-Dividend Date

―

MoonLake Immunotherapeutics as a current ratio of 9.27, with Debt / Equity ratio of 24.86%

Current Ratio

9.27

Quick Ratio

9.27

Debt to Market Cap

0.09

Net Debt to EBITDA

1.18

Interest Coverage Ratio

-33.78

In the past 12 months, MoonLake Immunotherapeutics has paid 611.00K in taxes.

Income Tax

611.00K

Effective Tax Rate

-0.00

MoonLake Immunotherapeutics EV to EBITDA ratio is -2.47, with an EV/FCF ratio of -2.63.

EV to Sales

0.00

EV to EBITDA

-2.47

EV to Free Cash Flow

-2.63

EV to Operating Cash Flow

-2.63

MoonLake Immunotherapeutics has $498.46M in cash and marketable securities with $101.62M in debt, giving a net cash position of $396.85M billion.

Cash & Marketable Securities

$498.46M

Total Debt

$101.62M

Net Cash

$396.85M

Net Cash Per Share

$4.66

Tangible Book Value Per Share

$4.47

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin

0.00%

Operating Margin

0.00%

Pretax Margin

0.00%

Net Profit Margin

0.00%

EBITDA Margin

0.00%

EBIT Margin

0.00%

The average price target for MoonLake Immunotherapeutics is $33.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

$33.00

Price Target Upside

205.56% Upside

Analyst Consensus

Strong Buy

Analyst Count

9

Revenue Growth Forecast

―

EPS Growth Forecast

-10.20%

Smart Score

8

AI Score

52